OMER - omeros.com Total Enterprise Value

Brandmark of Omeros Corp (OMER)

The price trend shown below illustrates the valuation dynamics of Omeros Corporation (OMER), which develops innovative therapies for severe nervous system pathologies. The current figure stands at 1499.76, however, FDA approval delays for its lead asset jeopardize the firm's solvency. The company's success relies on the implementation of a unique drug discovery system, while future growth is based on the commercial success of narsoplimab.

OMER - omeros.com Total Company Value over the range 11/23/2025 - 10/31/2026

Omeros - analytical breakdowns and key metrics (OMER)

- current quotes and average value forecast:
Stock Quotes Omeros Corp|OMER - Analyst Consensus Forecast
- market capitalization statistics:
Market Value Omeros|OMER - Total Company Value
- book capitalization data:
Accounting Value of a Share Omeros|OMER - Company Book Value|Capitalization to Book Value Ratio omeros.com|OMER - Company Total Assets
- debt level and financial liquidity data:
Debt to Capital Omeros Corporation|OMER - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Omeros Corp|OMER - Company Debts|Debt to Net Assets Ratio Omeros|OMER - Company Long-Term Debt|Short-Term Debt Omeros|Immediate Liquidity omeros.com
- earnings and market ratios statistics:
OMER - Company Net Income
Analysis of all company metrics:Omeros Corporation
Manufactured product of Omeros

Assessing the reliability of equity assets requires an analysis of the total enterprise value, combining market capitalization and net debt to uncover hidden credit risks. The sum of the market price and liabilities minus liquidity in the enterprise value forecast for Omeros Corporation (OMER) reflects the actual cost of acquiring the company, accounting for the vulnerability of its logistics and patent disputes, which allows for the determination of the asset's true investment attractiveness.

Competitors of Omeros Corporation (OMER)

BIIB - Real Price to Acquire Entire Company|Neurocrine Biosciences Inc - Enterprise Value|Total Enterprise Value Regencell Corp|Axsome Therapeutics (AXSM) - Total Company Value|acadia-pharm.com - Value Adjusted for Debt and Cash|Total Company Value Xenon|Business Value VKTX (Viking Therapeutics Inc)|Enterprise Value SUPN|CPRX - Total Enterprise Value|Denali Therapeutics - Real Price to Acquire Entire Company|Enterprise Value harmonybiosciences.com HRMY|BHVN - Total Company Value|Value Adjusted for Debt and Cash AMLX (Amylyx Pharmaceuticals Inc)|Trevi Pharma (TRVI) - Total Company Value|Total Enterprise Value Praxis Corp (PRAX)|Total Company Value Anavex Life Sciences|Total Enterprise Value ceribell.com CBLL|Total Company Value Prothena Biosciences (PRTA)|Real Price to Acquire Entire Company alector.com ALEC|Enterprise Value ANNX (Annexon Inc.)|Neurogene Therapeutics (NGNE) - Total Enterprise Value|ACIU - Total Company Value|Value Adjusted for Debt and Cash VYGR (voyagertherapeutics.com)|Neumora Therapeutics, Inc. (NMRA) - Total Company Value|Total Enterprise Value Scilex Holding (SCLX)|Total Company Value Tevogen Bio Holdings, Inc.|Alpha Cognition Corp (ACOG) - Company Buyout Price|Real Price to Acquire Entire Company CGTX (Cognition Therapeutics, Inc.)|IKT (inhibikase.com) - Value Adjusted for Debt and Cash|Enterprise Value SAVA (Cassava Sciences)|ASRT - Real Price to Acquire Entire Company|COYA - Total Company Value|Total Enterprise Value Vistagen Therapeutics|ovidrx.com (OVID) - Total Company Value|acumenpharm.com - Value Adjusted for Debt and Cash|Total Company Value CervoMed|Alterity Therapeutics Ltd - Full Business Value|Total Company Value Clene Inc. (CLNN)|PEPG - Total Enterprise Value|Total Company Value Jupiter Neurosciences JUNS|Value Adjusted for Debt and Cash RLMD|Annovis Bio - Enterprise Value|GRCE - Enterprise Value|AIFF (Firefly Neuroscience Inc) - Real Price to Acquire Entire Company|KLTO: Aggregate Business Value|NRSN (NeuroSense Therapeutics Ltd) - Enterprise Value|revivapharma.com (RVPH) - Company Buyout Price|Total Company Value MetaVia Inc (MTVA)|NRXS - Total Enterprise Value|Total Company Value Helius Medical Technologies HSDT|PASG: Business Value|NEUP - Total Company Value|Total Enterprise Value minervaneurosciences.com|Athira Pharma (ATHA) - Total Company Value|Real Price to Acquire Entire Company Addex Therapeutics Ltd.|ALZN (Alzamend Neuro Inc.) - Enterprise Value|Total Enterprise Value Cyclerion CYCN|Total Company Value Protagenic Therapeutics (PTIX)|KTTA (pasitheaclinics.com) - Value Adjusted for Debt and Cash|Total Company Value Cortigent CRGT|ATXI: Business Value|Brainstorm Cell Therapeutics, Inc. - Enterprise Value|Total Enterprise Value Cara Therapeutics Inc|CHRO (Chromocell Therapeutics) - Real Price to Acquire Entire Company|Eliem Therapeutics Inc. (ELYM) - Enterprise Value|Total Company Value Intra-Cellular Therapies Inc.|LBPH: Value Adjusted for Debt and Cash|Total Company Value Marinus (MRNS)|NKGN - Total Enterprise Value|Total Company Value NeuroBo Pharmaceuticals NRBO|sagerx.com (SAGE) - Total Enterprise Value|SNPX - Total Company Value|Trevena Inc. (TRVN) - Real Price to Acquire Entire Company|VIGL: Enterprise Value|Total Enterprise Value anewmeds.com (WENA)|Total Company Value Cerevel Therapeutics